Brainlab said today it launched a new high-res planning algorithm within its Brainlab Elements software to improve radiation dose conformity for treating brain tumors, and added that the algorithm is a result of its strategic collaboration Elekta (STO:EKTA B).
The Munich-based company’s Elements system operates with Elekta’s Agility multileaf collimator to compensate for the width of selected leaves and allow for better conformation to tumor shapes, and to reduce radiation dosing to organs at risk.
The new algorithm in the Elements software allows support of virtual leaf width capability with Agility on the Versa HD linear accelerator, Brainlab said. The newly implemented algorithm partially blocks collimator leaves along the vertical edge of tumor targets to reduce collimator leaves down to 1mm across the full treatment field of view for improved conformity.
“On a VersaHD, this technology now enables clinicians to achieve superior dose distribution, especially for small cranial targets. Cranial Elements and ExacTrac open the door for Elekta users to establish a Novalis program utilizing Versa HD, joining the elite community of linac-based radiosurgery users,” Brainlab CEO Stefan Vilsmeier said in a prepared statement.
“This latest collaborative effort demonstrates our mutual commitment to precision radiation treatment solutions for our customers. By leveraging the unique capabilities of Versa HD’s collimation system and better integration of ExacTrac in our workflow, we will further expand the radiosurgery capabilities of Versa HD and can bring greater benefits to healthcare clinics and patients,” Elekta chief strategy officer Maurits Wolleswinkel said in a prepared release.
Last December, Elekta and Brainlab announced an exclusive deal that made Brainlab the authorized distributor of Elekta’s stereotactic neurosurgery solutions.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.